Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében | Diagnosis and treatment of polycythaemia vera: state of the art [PDF]
, 2016 Absztrakt A polycythaemia vera a Philadelphia-negatív krónikus myeloid neoplasiák közé tartozó ritka neoplasia, amelyre az emelkedett vörösvérsejttömeg okozta hiperviszkozitás a jellemző.
Borbényi, Zita +2 more
core +1 more source
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Haematologica, 2016 Bone marrow fibrosis is a central pathological feature and World Health Organization major diagnostic criterion of myelofibrosis. Although bone marrow fibrosis is seen in a variety of malignant and non-malignant disease states, the deposition of ...
Abdallah Abou Zahr +7 more
doaj +1 more source
Haematologica, 2019 We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2). The study included 32 patients with polycythemia vera and 18 with primary
A. Sørensen +19 more
semanticscholar +1 more source
Extramedullary myeloid tumors in primary myelofibrosis [PDF]
, 1965 Philip Lieberman +2 more
openalex +1 more source
Thrombotic and hemorrhagic complications in idiopathic erythrocytosis [PDF]
, 2017 We report clinical features of a large cohort of patients with IE compared to a cohort of patients with PV, focusing on the thrombotic and hemorrhagic ...
Bertozzi, Irene +5 more
core +1 more source
eJHaem, Volume 6, Issue 5, October 2025.ABSTRACT Background The emergence of JAK2‐mutated myeloproliferative neoplasms (MPNs) after remission from acute myeloid leukaemia (AML) is exceedingly rare. Case Description This case series describes two patients who developed JAK2‐mutated MPNs years after achieving AML remission, each retaining persistent TET2 and SRSF2 mutations while losing AML ...
Mark Anthony Turingan +5 more
wiley +1 more source
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.
Blood, 2019 Anemia of lower-risk myelodysplastic syndromes (MDSs) and primary myelofibrosis (PMF) generally becomes resistant to available treatments, leading to red blood cell (RBC) transfusions, iron overload, shortened survival, and poor quality of life.
P. Fenaux, J. Kiladjian, U. Platzbecker
semanticscholar +1 more source
Use of Testosterone and Busulfan in the Treatment of Myelofibrosis with Myeloid Metaplasia [PDF]
, 1964 Richard T. Silver +3 more
openalex +1 more source
Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies [PDF]
, 2015 Gene expression profiling has implicated several intracellular signalling cascades, including the JAK/STAT pathway, in the pathogenesis of particular subtypes of lymphoma.
Gandhi, Maher K., Scott, Linda M.
core +1 more source
What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog
Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson +5 more
wiley +1 more source